Litigation prescribed: The Tipline for 24 August 2022

Pharmaceutical companies have played a key role in funding the antitrust bar for several years, but scrutiny of their purportedly anticompetitive conduct took a back seat for a while amid all the Big Tech talk. Drugmakers have faced some hefty setbacks over the last few days, however, with federal judges conclusively refusing to toss claims against Indivior, Gilead Sciences, Cipla, Mylan and Pfizer while Teva Pharmaceuticals was hit with another class action complaint relating to its multiple sclerosis treatment. Today’s Tipline also looks at revisions to a journalism-focused antitrust bill plus a request from DirecTV subscribers to finally move forward as two classes.

Unlock unlimited access to all Global Competition Review content